Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model
We have compared four cell-based tumour vaccine strategies in prevention experiments using the B16-F10 melanoma model. Two of these are thought to favour the direct antigen presentation pathway (B16-F10 expressing B7.1 and hybrids made between B16-F10 cells and macrophages) and the other two strateg...
Gespeichert in:
| Veröffentlicht in: | Gene therapy 1998-11, Vol.5 (11), p.1447-1454 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1454 |
|---|---|
| container_issue | 11 |
| container_start_page | 1447 |
| container_title | Gene therapy |
| container_volume | 5 |
| creator | SOUBERBIELLE, B. E WESTBY, M GANZ, S KAYAGA, J MENDES, R MORROW, W. J. W DALGLEISH, A. G |
| description | We have compared four cell-based tumour vaccine strategies in prevention experiments using the B16-F10 melanoma model. Two of these are thought to favour the direct antigen presentation pathway (B16-F10 expressing B7.1 and hybrids made between B16-F10 cells and macrophages) and the other two strategies are thought to act by an indirect pathway of presentation (allogeneic tumour cells and autologous tumour cells combined with a powerful adjuvant (Provax-IDEC Pharmaceuticals)). Only the two latter vaccines promoted antitumour activity, whereas the vaccines consisting of B7.1-expressing tumour cells or the hybrid vaccine failed to provide any antitumour activity. Recently human trials have commenced using transfection of the B7.1 molecule, as well as employing the hybrid technology to make tumour-B cell hybrids or tumour and dendritic cell hybrids. Our results suggest that these approaches could be disappointing in the clinics if not optimised. |
| doi_str_mv | 10.1038/sj.gt.3300747 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69161733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17108722</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-369c1f3f5cd30f763077a44aec92a9895242bb828acefff40443c849aa2804b13</originalsourceid><addsrcrecordid>eNqFkc2LFDEQxYMo67h69Cg0KN56rEoy-Tjq4KqwIIieQ00mGXvo7oxJWvC_N8s2Cl48FVX141GvHmPPEbYIwrwp5-2pboUA0FI_YBuUWvU7qfhDtgGrbK-Rm8fsSSlnAJDa8Ct2Za0AbvWGfdmn6UJ5KGnuUuxiWnJXaqYaTkMorc9dXaa76U_yfpipDo0c5q5-D907VP0NQjeFkeY0UTelYxifskeRxhKerfWafbt5_3X_sb_9_OHT_u1t7yXuai-U9RhF3PmjgKiVAK1JSgrecrLG7rjkh4PhhnyIMUqQUngjLRE3IA8ortnre91LTj-WUKqbhuLD2G4JaSlOWVSohfgviBrBaM4b-PIf8Nycz82E40q2lyIo3aj-nvI5lZJDdJc8TJR_OQR3F4krZ3eqbo2k8S9W1eUwheMfes2g7V-teyqexphp9kP5K6oAUQrxGxUOkho</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644621067</pqid></control><display><type>article</type><title>Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>SOUBERBIELLE, B. E ; WESTBY, M ; GANZ, S ; KAYAGA, J ; MENDES, R ; MORROW, W. J. W ; DALGLEISH, A. G</creator><creatorcontrib>SOUBERBIELLE, B. E ; WESTBY, M ; GANZ, S ; KAYAGA, J ; MENDES, R ; MORROW, W. J. W ; DALGLEISH, A. G</creatorcontrib><description>We have compared four cell-based tumour vaccine strategies in prevention experiments using the B16-F10 melanoma model. Two of these are thought to favour the direct antigen presentation pathway (B16-F10 expressing B7.1 and hybrids made between B16-F10 cells and macrophages) and the other two strategies are thought to act by an indirect pathway of presentation (allogeneic tumour cells and autologous tumour cells combined with a powerful adjuvant (Provax-IDEC Pharmaceuticals)). Only the two latter vaccines promoted antitumour activity, whereas the vaccines consisting of B7.1-expressing tumour cells or the hybrid vaccine failed to provide any antitumour activity. Recently human trials have commenced using transfection of the B7.1 molecule, as well as employing the hybrid technology to make tumour-B cell hybrids or tumour and dendritic cell hybrids. Our results suggest that these approaches could be disappointing in the clinics if not optimised.</description><identifier>ISSN: 0969-7128</identifier><identifier>EISSN: 1476-5462</identifier><identifier>DOI: 10.1038/sj.gt.3300747</identifier><identifier>PMID: 9930297</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Animals ; Antigen Presentation ; B7-1 Antigen ; Biological and medical sciences ; Biotechnology ; Cancer Vaccines - therapeutic use ; Cell hybrids ; Chemotherapy, Adjuvant ; Combined vaccines ; Dendritic cells ; Female ; Fundamental and applied biological sciences. Psychology ; Gene therapy ; Genetic Therapy - methods ; Health. Pharmaceutical industry ; Hybridomas - immunology ; Hybridomas - pathology ; Industrial applications and implications. Economical aspects ; Macrophages ; Macrophages - immunology ; Melanoma ; Melanoma, Experimental - drug therapy ; Melanoma, Experimental - immunology ; Melanoma, Experimental - prevention & control ; Mice ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Survival Rate ; Transfection ; Tumors ; Vaccination - methods ; Vaccines</subject><ispartof>Gene therapy, 1998-11, Vol.5 (11), p.1447-1454</ispartof><rights>1999 INIST-CNRS</rights><rights>Macmillan Publishers Limited 1998.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-369c1f3f5cd30f763077a44aec92a9895242bb828acefff40443c849aa2804b13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1601143$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9930297$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SOUBERBIELLE, B. E</creatorcontrib><creatorcontrib>WESTBY, M</creatorcontrib><creatorcontrib>GANZ, S</creatorcontrib><creatorcontrib>KAYAGA, J</creatorcontrib><creatorcontrib>MENDES, R</creatorcontrib><creatorcontrib>MORROW, W. J. W</creatorcontrib><creatorcontrib>DALGLEISH, A. G</creatorcontrib><title>Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model</title><title>Gene therapy</title><addtitle>Gene Ther</addtitle><description>We have compared four cell-based tumour vaccine strategies in prevention experiments using the B16-F10 melanoma model. Two of these are thought to favour the direct antigen presentation pathway (B16-F10 expressing B7.1 and hybrids made between B16-F10 cells and macrophages) and the other two strategies are thought to act by an indirect pathway of presentation (allogeneic tumour cells and autologous tumour cells combined with a powerful adjuvant (Provax-IDEC Pharmaceuticals)). Only the two latter vaccines promoted antitumour activity, whereas the vaccines consisting of B7.1-expressing tumour cells or the hybrid vaccine failed to provide any antitumour activity. Recently human trials have commenced using transfection of the B7.1 molecule, as well as employing the hybrid technology to make tumour-B cell hybrids or tumour and dendritic cell hybrids. Our results suggest that these approaches could be disappointing in the clinics if not optimised.</description><subject>Animals</subject><subject>Antigen Presentation</subject><subject>B7-1 Antigen</subject><subject>Biological and medical sciences</subject><subject>Biotechnology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Cell hybrids</subject><subject>Chemotherapy, Adjuvant</subject><subject>Combined vaccines</subject><subject>Dendritic cells</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene therapy</subject><subject>Genetic Therapy - methods</subject><subject>Health. Pharmaceutical industry</subject><subject>Hybridomas - immunology</subject><subject>Hybridomas - pathology</subject><subject>Industrial applications and implications. Economical aspects</subject><subject>Macrophages</subject><subject>Macrophages - immunology</subject><subject>Melanoma</subject><subject>Melanoma, Experimental - drug therapy</subject><subject>Melanoma, Experimental - immunology</subject><subject>Melanoma, Experimental - prevention & control</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neoplasm Transplantation</subject><subject>Survival Rate</subject><subject>Transfection</subject><subject>Tumors</subject><subject>Vaccination - methods</subject><subject>Vaccines</subject><issn>0969-7128</issn><issn>1476-5462</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2LFDEQxYMo67h69Cg0KN56rEoy-Tjq4KqwIIieQ00mGXvo7oxJWvC_N8s2Cl48FVX141GvHmPPEbYIwrwp5-2pboUA0FI_YBuUWvU7qfhDtgGrbK-Rm8fsSSlnAJDa8Ct2Za0AbvWGfdmn6UJ5KGnuUuxiWnJXaqYaTkMorc9dXaa76U_yfpipDo0c5q5-D907VP0NQjeFkeY0UTelYxifskeRxhKerfWafbt5_3X_sb_9_OHT_u1t7yXuai-U9RhF3PmjgKiVAK1JSgrecrLG7rjkh4PhhnyIMUqQUngjLRE3IA8ortnre91LTj-WUKqbhuLD2G4JaSlOWVSohfgviBrBaM4b-PIf8Nycz82E40q2lyIo3aj-nvI5lZJDdJc8TJR_OQR3F4krZ3eqbo2k8S9W1eUwheMfes2g7V-teyqexphp9kP5K6oAUQrxGxUOkho</recordid><startdate>19981101</startdate><enddate>19981101</enddate><creator>SOUBERBIELLE, B. E</creator><creator>WESTBY, M</creator><creator>GANZ, S</creator><creator>KAYAGA, J</creator><creator>MENDES, R</creator><creator>MORROW, W. J. W</creator><creator>DALGLEISH, A. G</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7QO</scope><scope>7T5</scope><scope>7X8</scope></search><sort><creationdate>19981101</creationdate><title>Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model</title><author>SOUBERBIELLE, B. E ; WESTBY, M ; GANZ, S ; KAYAGA, J ; MENDES, R ; MORROW, W. J. W ; DALGLEISH, A. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-369c1f3f5cd30f763077a44aec92a9895242bb828acefff40443c849aa2804b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antigen Presentation</topic><topic>B7-1 Antigen</topic><topic>Biological and medical sciences</topic><topic>Biotechnology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Cell hybrids</topic><topic>Chemotherapy, Adjuvant</topic><topic>Combined vaccines</topic><topic>Dendritic cells</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene therapy</topic><topic>Genetic Therapy - methods</topic><topic>Health. Pharmaceutical industry</topic><topic>Hybridomas - immunology</topic><topic>Hybridomas - pathology</topic><topic>Industrial applications and implications. Economical aspects</topic><topic>Macrophages</topic><topic>Macrophages - immunology</topic><topic>Melanoma</topic><topic>Melanoma, Experimental - drug therapy</topic><topic>Melanoma, Experimental - immunology</topic><topic>Melanoma, Experimental - prevention & control</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neoplasm Transplantation</topic><topic>Survival Rate</topic><topic>Transfection</topic><topic>Tumors</topic><topic>Vaccination - methods</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SOUBERBIELLE, B. E</creatorcontrib><creatorcontrib>WESTBY, M</creatorcontrib><creatorcontrib>GANZ, S</creatorcontrib><creatorcontrib>KAYAGA, J</creatorcontrib><creatorcontrib>MENDES, R</creatorcontrib><creatorcontrib>MORROW, W. J. W</creatorcontrib><creatorcontrib>DALGLEISH, A. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SOUBERBIELLE, B. E</au><au>WESTBY, M</au><au>GANZ, S</au><au>KAYAGA, J</au><au>MENDES, R</au><au>MORROW, W. J. W</au><au>DALGLEISH, A. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model</atitle><jtitle>Gene therapy</jtitle><addtitle>Gene Ther</addtitle><date>1998-11-01</date><risdate>1998</risdate><volume>5</volume><issue>11</issue><spage>1447</spage><epage>1454</epage><pages>1447-1454</pages><issn>0969-7128</issn><eissn>1476-5462</eissn><abstract>We have compared four cell-based tumour vaccine strategies in prevention experiments using the B16-F10 melanoma model. Two of these are thought to favour the direct antigen presentation pathway (B16-F10 expressing B7.1 and hybrids made between B16-F10 cells and macrophages) and the other two strategies are thought to act by an indirect pathway of presentation (allogeneic tumour cells and autologous tumour cells combined with a powerful adjuvant (Provax-IDEC Pharmaceuticals)). Only the two latter vaccines promoted antitumour activity, whereas the vaccines consisting of B7.1-expressing tumour cells or the hybrid vaccine failed to provide any antitumour activity. Recently human trials have commenced using transfection of the B7.1 molecule, as well as employing the hybrid technology to make tumour-B cell hybrids or tumour and dendritic cell hybrids. Our results suggest that these approaches could be disappointing in the clinics if not optimised.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>9930297</pmid><doi>10.1038/sj.gt.3300747</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0969-7128 |
| ispartof | Gene therapy, 1998-11, Vol.5 (11), p.1447-1454 |
| issn | 0969-7128 1476-5462 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69161733 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Animals Antigen Presentation B7-1 Antigen Biological and medical sciences Biotechnology Cancer Vaccines - therapeutic use Cell hybrids Chemotherapy, Adjuvant Combined vaccines Dendritic cells Female Fundamental and applied biological sciences. Psychology Gene therapy Genetic Therapy - methods Health. Pharmaceutical industry Hybridomas - immunology Hybridomas - pathology Industrial applications and implications. Economical aspects Macrophages Macrophages - immunology Melanoma Melanoma, Experimental - drug therapy Melanoma, Experimental - immunology Melanoma, Experimental - prevention & control Mice Mice, Inbred C57BL Neoplasm Transplantation Survival Rate Transfection Tumors Vaccination - methods Vaccines |
| title | Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A34%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20four%20strategies%20for%20tumour%20vaccination%20in%20the%20B16-F10%20melanoma%20model&rft.jtitle=Gene%20therapy&rft.au=SOUBERBIELLE,%20B.%20E&rft.date=1998-11-01&rft.volume=5&rft.issue=11&rft.spage=1447&rft.epage=1454&rft.pages=1447-1454&rft.issn=0969-7128&rft.eissn=1476-5462&rft_id=info:doi/10.1038/sj.gt.3300747&rft_dat=%3Cproquest_cross%3E17108722%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644621067&rft_id=info:pmid/9930297&rfr_iscdi=true |